Alpine's Pipeline

We have a diverse pipeline of multi-targeted therapies in development for both inflammatory disease and oncology.

Wholly Owned Programs

IMMUNO-ONCOLOGY

davoceticept (ALPN-202)

Conditional CD28 Costimulator and Dual PD-L1/CTLA-4 Inhibitor
PreclinicalPhase 1Phase 2Phase 3

Monotherapy, Advanced Malignancies

50%
PreclinicalPhase 1Phase 2Phase 3

KEYTRUDA® Combination Advanced Malignancies

40%

Details

Commmercial Rights:

Alpine-Immune-Logo-Color

Supply Agreement:

Davoceticept is engineered to provide direct T cell costimulation and dual checkpoint inhibition to enable the immune system to mount a robust anti-tumor response.

We are currently enrolling NEON-1, a Phase 1 study of davoceticept in patients with advanced malignancies (NCT04186637).

We are currently enrolling NEON-2, a Phase 1 combination study of davoceticept with KEYTRUDA® (pembrolizumab) in patients with advanced malignancies (NCT04920383).

Learn More

INFLAMMATORY DISEASES

ALPN-303

Dual B Cell Cytokine Antagonist of BAFF and APRIL
PreclinicalPhase 1Phase 2Phase 3

B cell-mediated diseases

38%

Details

Commmercial Rights:

Alpine-Immune-Logo-Color

ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases.

We are currently enrolling in a Phase 1 study of ALPN-303 in healthy volunteers (NCT05034484). This study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALPN-303. Multiple dose levels will be tested to help assess ALPN-303’s potential for the treatment of inflammatory diseases.

Learn More

Partnered Programs

acazicolcept (ALPN-101)

Dual CD28/ICOS Antagonist
PreclinicalPhase 1Phase 2Phase 3

Systemic lupus erythematosus

70%

Details

Partners:

Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.

We are currently enrolling Synergy, a Phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (NCT04835441). This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept.

Learn More

Discovery Collaboration

Immunology
PreclinicalsPhase 1Phase 2Phase 3

Undisclosed

20%

Next Generation TCR T-cell Therapies

PreclinicalsPhase 1Phase 2Phase 3

Undisclosed

20%
Adaptimmune logo

For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filingscorporate presentations, and scientific publications.

Join us in the discovery and development of next-generation immunotherapies.

Current job openingsLearn more about Alpine